RMD ResMed Inc.

ResMed Announces SaaS Leadership Change

ResMed Announces SaaS Leadership Change

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed’s SaaS business

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business, effective immediately. Raj Sodhi will be leaving full-time employment at ResMed, effective September 1.

Bobby has over 25 years of experience across medical and technology industries, most currently serving as ResMed’s Chief Technology Officer (CTO), with strong experience building and leading high-performing teams to accelerate the adoption of digital platforms across enterprises. From February 2016 until April 2018, Bobby served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care. ResMed will commence a search process for a new CTO immediately; Bobby will remain in the CTO role until a replacement is found.

“As we look ahead to 2025, we believe the future of healthcare is outside the hospital and we have an amazing mission to improve over 250 million lives,” said Mick Farrell, ResMed’s CEO. “We must accelerate our efforts to bring software technology, along with digital and commercial innovation, to these care settings. Digital solutions, scalable digital platforms, and software embedded into our customers’ workflows are critical to our growth strategy – Bobby’s experience as ResMed’s CTO, his hands-on experience with Brightree, and his strong background across many industries makes him the right leader to accelerate our SaaS business to meet our goals for 2025 and beyond.”

“I’d like to thank Raj for the incredible work he’s done over the past nine years at ResMed,” continued Farrell. “Raj played an important role in developing the healthcare informatics function at ResMed, a function that helped to transform the company on our path to becoming the leader in digital health. He also helped to craft the SaaS strategy and lead multiple acquisitions that established the foundation for us to scale and grow our SaaS business in home medical equipment, skilled nursing facilities, home health, hospice, private duty homecare, and beyond.”

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investorsFor media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 858.836.6798



EN
25/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

ResMed Inc: 2 directors

Two Directors at ResMed Inc sold 2,050 shares at between 251.310USD and 260.000USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

 PRESS RELEASE

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today an...

 PRESS RELEASE

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

 PRESS RELEASE

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

 PRESS RELEASE

Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch